A new excuse for pharma to avoid the Twitterverse, thanks to the FDA

Any brand managers eager to jump into Twitter as soon as the FDA gave the go-ahead? No such luck. Last week's social media guidance on risk disclosures may have cleared up some of the regulatory fog, but in this case, clarity isn't a positive.

By requiring every brand-oriented tweet to include risks and benefits, the FDA left drug marketers almost no room to add more. By Digitas Health's calculation, packing those disclosures together can take 135 of the 140 characters Twitter allows. That leaves room for one four-letter word. And forget engaging in conversation: no way to squeeze in a chat partner's Twitter handle.

Pharma marketers could be making lists of four-letter words right now. With a few choice ones directed at the FDA. Read more from FiercePharmaMarketing >>